Aytu BioPharma (AYTU) awards director 10,000 restricted stock shares

Rhea-AI Filing Summary

DOCKERY CARL reported acquisition or exercise transactions in this Form 4 filing.

Aytu BioPharma director Carl Dockery received a grant of 10,000 shares of restricted common stock on July 28, 2026. The shares vest on July 28, 2027, and his directly held position increased to 31,152 shares after this compensation-related award.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider DOCKERY CARL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	10,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 31,152 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted stock, which vest on July 28, 2027.

Key Figures

Restricted stock granted: 10,000 shares Shares held after grant: 31,152 shares Transaction date: July 28, 2026 +2 more

5 metrics

Restricted stock granted 10,000 shares Grant of restricted common stock on July 28, 2026

Shares held after grant 31,152 shares Direct holdings following the reported transaction

Transaction date July 28, 2026 Date of restricted stock grant to director Carl Dockery

Vesting date July 28, 2027 Scheduled vesting date for the 10,000 restricted shares

Reported price per share $0.0000 Per-share transaction price field for the restricted stock grant

Key Terms

restricted stock, Grant, award, or other acquisition, Rule 10b5-1

3 terms

restricted stock financial

"Footnote states: Grant of restricted stock, which vest on July 28, 2027."

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Grant, award, or other acquisition financial

"Transaction code description is Grant, award, or other acquisition."

Rule 10b5-1 regulatory

"aff_10b5_one field indicates Rule 10b5-1 trading plan status."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 04:32 PM Accepted by SEC EDGAR 07/30/2026 - 04:31 PM Learn about SEC filing dates

FAQ

What insider transaction did AYTU report for director Carl Dockery?

Aytu BioPharma reported that director Carl Dockery received a grant of 10,000 shares of restricted common stock on July 28, 2026. The award is compensation-related and increases his directly held stake to 31,152 shares after the grant.

How many AYTU shares were granted to Carl Dockery in this Form 4?

Carl Dockery was granted 10,000 shares of Aytu BioPharma common stock as restricted stock. These shares are subject to vesting conditions and are scheduled to vest on July 28, 2027, according to the footnote in the filing.

When do Carl Dockery’s AYTU restricted shares vest?

The 10,000 shares of restricted stock granted to Carl Dockery vest on July 28, 2027. Until that vesting date, the award remains subject to its restriction terms as described in the filing’s footnote about the grant.

How many AYTU shares does Carl Dockery hold after this grant?

Following the restricted stock grant, Carl Dockery directly holds 31,152 shares of Aytu BioPharma common stock. This total reflects his position immediately after the 10,000-share award reported in the Form 4 insider transaction.

Was the AYTU stock grant to Carl Dockery made under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is marked as not selected, indicating the grant was not reported as being made under a Rule 10b5-1 trading plan. It is disclosed as a compensation-related restricted stock award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOCKERY CARL

(Last) (First) (Middle)

C/O AYTU BIOPHARMA, INC.

7900 EAST UNION AVENUE, SUITE 920

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AYTU BIOPHARMA, INC [ AYTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		A		10,000(1)	A	$0	31,152	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock, which vest on July 28, 2027.

	/s/ Ryan J. Selhorn as attorney-in-fact for Carl C. Dockery	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)